Detalles de la búsqueda
1.
Systematic vitamin D supplementation is associated with improved outcomes and reduced thyroid adverse events in patients with cancer treated with immune checkpoint inhibitors: results from the prospective PROVIDENCE study.
Cancer Immunol Immunother
; 72(11): 3707-3716, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37638980
2.
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50.
Cancer Immunol Immunother
; 69(11): 2209-2221, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-32474768
3.
Sarcoid-like reaction mimicking disease progression in an ALK-positive lung cancer patient receiving lorlatinib.
Invest New Drugs
; 37(2): 360-363, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30066208
4.
The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response.
Br J Cancer
; 119(10): 1252-1258, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30397287
5.
Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access program.
Tumour Biol
; 40(11): 1010428318815047, 2018 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-30486741
6.
Metabolic complete response with vinflunine as second-line therapy in a kidney-transplanted patient with advanced urothelial carcinoma: a case report.
BMC Cancer
; 16: 626, 2016 08 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27519420
7.
Radiotherapy of non-small-cell lung cancer in the era of EGFR gene mutations and EGF receptor tyrosine kinase inhibitors.
Future Oncol
; 11(16): 2329-42, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26260811
8.
Crizotinib Resensitization by Compound Mutation.
N Engl J Med
; 374(18): 1790, 2016 05 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-27144863
9.
A case series of non-small cell lung cancer patients with EGFR or HER2 exon 20 insertion in Li Fraumeni syndrome.
Tumori
; : 3008916241255485, 2024 May 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-38779904
10.
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed.
Eur J Cancer
; 202: 114006, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38489861
11.
Thirty-day mortality in hospitalised patients with lung cancer: incidence and predictors.
BMJ Support Palliat Care
; 2023 Sep 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-37666650
12.
Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer.
Clin Cancer Res
; 29(14): 2714-2724, 2023 07 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-37125965
13.
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors.
Tumori
; 108(1): 47-55, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-34002648
14.
Transient asymptomatic pulmonary opacities and interstitial lung disease in EGFR-mutated non-small cell lung cancer treated with osimertinib.
Tumori
; 108(6): 592-599, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34585625
15.
Dynamic Evaluation of Circulating miRNA Profile in EGFR-Mutated NSCLC Patients Treated with EGFR-TKIs.
Cells
; 10(6)2021 06 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-34208765
16.
Monitoring cfDNA in Plasma and in Other Liquid Biopsies of Advanced EGFR Mutated NSCLC Patients: A Pilot Study and a Review of the Literature.
Cancers (Basel)
; 13(21)2021 Oct 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-34771566
17.
Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter study.
Thorac Cancer
; 12(6): 880-889, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33527756
18.
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy.
J Immunother Cancer
; 9(4)2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33827906
19.
The Prognostic Role of High Blood Cholesterol in Advanced Cancer Patients Treated With Immune Checkpoint Inhibitors.
J Immunother
; 43(6): 196-203, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32404654
20.
Emergence of a HER2-amplified clone during disease progression in an ALK-rearranged NSCLC patient treated with ALK-inhibitors: a case report.
Transl Lung Cancer Res
; 9(3): 787-792, 2020 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-32676339